UCB, Eli Lilly-backed ViaNautis raises $25M in Series A to develop genetic nanomedicines

UK-based biotech Via­Nautis Bio has bagged $25 mil­lion in a Se­ries A round sup­port­ed by two Big Phar­ma com­pa­nies to ad­vance its nanomed­i­cine tech­nol­o­gy with an ear­ly fo­cus on RNA-based treat­ments.

Via­Nautis — pre­vi­ous­ly known as So­maServe — was spun out of Uni­ver­si­ty Col­lege Lon­don in 2018. Its Se­ries A round was joint­ly led by 4BIO Cap­i­tal, BGF, and UCB Ven­tures. Oth­er con­trib­u­tors in­clud­ed the Cys­tic Fi­bro­sis Foun­da­tion and Eli Lil­ly, as well as ex­ist­ing in­vestors Ori­gin Cap­i­tal, Meltwind and O2H.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.